发布求助
文献互助 智能选刊 最新文献

Immunotherapy最新文献

筛选
英文 中文
Are immune checkpoint inhibitors safe and effective in lung cancer patients with pre-existing interstitial lung disease? 免疫检查点抑制剂对已有间质性肺病的肺癌患者是否安全有效？
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-03-21 DOI: 10.2217/imt-2023-0147
Lin Zhu, Rong Gao, Han Li, Yahui Zheng, Junling Yang
{"title":"Are immune checkpoint inhibitors safe and effective in lung cancer patients with pre-existing interstitial lung disease?","authors":"Lin Zhu, Rong Gao, Han Li, Yahui Zheng, Junling Yang","doi":"10.2217/imt-2023-0147","DOIUrl":"10.2217/imt-2023-0147","url":null,"abstract":"<p><p><b>Aim:</b> This study aims to clarify the efficacy and adverse effects of immune checkpoint inhibitors (ICIs) in the lung cancer patients with a history of interstitial lung disease (ILD). <b>Methods:</b> From the inception of the database to 4 April 2023, we systematically searched the four databases. <b>Results:</b> The objective remission rate, disease control rate, incidence of immune-associated pneumonitis (ICIP) in the combined ILD group were significantly higher than those in the non-combined ILD group. There were no significant differences between the two groups in progression-free survival, overall survival, renal insufficiency, thyroid dysfunction and gastrointestinal toxicity. <b>Conclusion:</b> Generally, a pre-existing ILD history can increase the efficacy and incidence of ICIs' adverse reactions. Therefore, ICIs should be administered with caution.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"465-480"},"PeriodicalIF":2.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140174513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Facilitated subcutaneous immunoglobulin treatment patterns in pediatric patients with primary immunodeficiency diseases. 原发性免疫缺陷病儿科患者的皮下注射免疫球蛋白治疗模式。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-02-16 DOI: 10.2217/imt-2023-0305
Monika Mach-Tomalska, Anna Pituch-Noworolska, Ewa Bień, Magdalena Malanowska, Edyta Machura, Anna Pukas-Bochenek, Ewelina Chrobak, Małgorzata Pac, Barbara Pietrucha, Szymon Drygała, Marta Kamieniak, Jakub Kasprzak, Edyta Heropolitańska-Pliszka
{"title":"Facilitated subcutaneous immunoglobulin treatment patterns in pediatric patients with primary immunodeficiency diseases.","authors":"Monika Mach-Tomalska, Anna Pituch-Noworolska, Ewa Bień, Magdalena Malanowska, Edyta Machura, Anna Pukas-Bochenek, Ewelina Chrobak, Małgorzata Pac, Barbara Pietrucha, Szymon Drygała, Marta Kamieniak, Jakub Kasprzak, Edyta Heropolitańska-Pliszka","doi":"10.2217/imt-2023-0305","DOIUrl":"10.2217/imt-2023-0305","url":null,"abstract":"<p><p><b>Aim:</b> This retrospective study investigated real-world hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) treatment patterns in pediatric patients with primary immunodeficiency diseases (PIDs) in Poland. <b>Methods:</b> Clinical and demographic information, fSCIG treatment parameters and clinical outcomes were extracted from medical records of 28 participants (aged ≤18 years) with PIDs who received fSCIG. <b>Results:</b> 18 participants (64.3%) started fSCIG with a ramp-up (median duration: 35.5 days). 27 patients (96.4%) were administered fSCIG every 4 weeks and one patient every 3 weeks. 25 patients (89.3%) used one infusion site. No serious bacterial infections occurred. <b>Conclusion:</b> Data support the feasibility of administering fSCIG to children and adolescents with PIDs every 3-4 weeks using a single infusion site and indicate flexibility in modifying fSCIG infusion parameters. <b>Clinical Trial Registration:</b> NCT04636502 (ClinicalTrials.gov).</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"391-403"},"PeriodicalIF":2.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rare case of daratumumab-associated encephalopathy in multiple myeloma. 一例罕见的多发性骨髓瘤达拉曲单抗相关脑病病例。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-03-05 DOI: 10.2217/imt-2023-0321
Jingjing Xiang, Zirui Hong, Yu Zhang, Junfa Chen, Jianping Shen, Ni Zhu
{"title":"A rare case of daratumumab-associated encephalopathy in multiple myeloma.","authors":"Jingjing Xiang, Zirui Hong, Yu Zhang, Junfa Chen, Jianping Shen, Ni Zhu","doi":"10.2217/imt-2023-0321","DOIUrl":"10.2217/imt-2023-0321","url":null,"abstract":"<p><p><b>Aim:</b> Daratumumab, a CD38 monoclonal antibody, has been widely used in patients with multiple myeloma. Although a variety of adverse events have been reported, consciousness impairment has not been reported yet. We report a case of encephalopathy associated with daratumumab. <b>Case presentation:</b> A 57-year-old male, diagnosed with relapsed multiple myeloma, was treated with daratumumab. He developed a loss of consciousness after the first administration. Cerebral spinal fluid and magnetic resonance imaging of the brain suggested encephalopathy. <b>Conclusion:</b> It is recommended to be aware of rare but life threatening side effects of daratumumab. We present a case of rare encephalopathy characterized by consciousness disorder associated with daratumumab, which was successfully resolved on prompt institution of steroids, although the mechanism was unknown.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"447-452"},"PeriodicalIF":2.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140027997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Established and emerging biomarkers of immunotherapy in renal cell carcinoma. 肾细胞癌免疫疗法的既有和新兴生物标记物。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-01-24 DOI: 10.2217/imt-2023-0267
Yash Jani, Caroline S Jansen, Margo B Gerke, Mehmet Asim Bilen
{"title":"Established and emerging biomarkers of immunotherapy in renal cell carcinoma.","authors":"Yash Jani, Caroline S Jansen, Margo B Gerke, Mehmet Asim Bilen","doi":"10.2217/imt-2023-0267","DOIUrl":"10.2217/imt-2023-0267","url":null,"abstract":"<p><p>Immunotherapies, such as immune checkpoint inhibitors, have heralded impressive progress for patient care in renal cell carcinoma (RCC). Despite this success, some patients' disease fails to respond, and other patients experience significant side effects. Thus, development of biomarkers is needed to ensure that patients can be selected to maximize benefit from immunotherapies. Improving clinicians' ability to predict which patients will respond to immunotherapy and which are most at risk of adverse events - namely through clinical biomarkers - is indispensable for patient safety and therapeutic efficacy. Accordingly, an evolving suite of therapeutic biomarkers continues to be investigated. This review discusses biomarkers for immunotherapy in RCC, highlighting current practices and emerging innovations, aiming to contribute to improved outcomes for patients with RCC.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"405-426"},"PeriodicalIF":2.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139540944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between sex and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. 性别与免疫检查点抑制剂疗效之间的关系：系统综述与荟萃分析。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-02-29 DOI: 10.2217/imt-2023-0307
Jianxiong Lai, Xiaohong Kuang, Yi Fu, Jian Li
{"title":"Association between sex and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis.","authors":"Jianxiong Lai, Xiaohong Kuang, Yi Fu, Jian Li","doi":"10.2217/imt-2023-0307","DOIUrl":"10.2217/imt-2023-0307","url":null,"abstract":"<p><p><b>Aim:</b> To explore the association between sex and immune checkpoint inhibitors (ICIs). <b>Materials & methods:</b> We assessed the difference in survival outcomes from ICIs between sexes using an interaction test. <b>Results:</b> 108 studies representing 70,243 patients were included. In the first-line setting, the pooled interaction HR was 0.97 (95% CI: 0.91-1.04). In the subsequent-line setting, the pooled interaction HR was 0.85 (95% CI: 0.77-0.95). When ICIs were given as perioperative therapy or as systemic therapy in patients with positive PD-L1 expression, both men and women obtained equal survival benefits. <b>Conclusion:</b> Both sex, line of therapy, cancer (sub)type and PD-L1 status should be taken into account in the assessment of risk versus benefit when deciding to offer ICIs to patients.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"481-495"},"PeriodicalIF":2.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139989895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bimekizumab for the treatment of psoriasis. 用于治疗银屑病的 Bimekizumab。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-03-20 DOI: 10.2217/imt-2023-0240
Molly Thapar, Milan Patel, Kenneth Gordon
{"title":"Bimekizumab for the treatment of psoriasis.","authors":"Molly Thapar, Milan Patel, Kenneth Gordon","doi":"10.2217/imt-2023-0240","DOIUrl":"10.2217/imt-2023-0240","url":null,"abstract":"<p><p>Psoriasis is a chronic inflammatory skin condition characterized by Th17 T cell-mediated inflammation. An emerging treatment option for psoriasis is bimekizumab, a humanized monoclonal antibody targeting cytokines IL-17A and IL-17F. Phase I trials evaluating bimekizumab reported strong safety, tolerability, and clinical efficacy with most common treatment emergent adverse events being mild to moderate in nature. Phase II trials evaluated dosing intervals, revealing that higher dosages or more frequent administration of bimekizumab resulted in minimal increases in adverse events. Phase III trials and open label extension studies demonstrated a rapid, sustained clinical response when compared with placebo and active comparators. Bimekizumab shows strong efficacy in the treatment of psoriasis and has potential in the treatment of other Th17-mediated pathologies.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"431-446"},"PeriodicalIF":2.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140174514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Upadacitinib for the treatment of moderate-to-severe Crohn's disease. 用于治疗中重度克罗恩病的奥帕他替尼。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-02-16 DOI: 10.2217/imt-2023-0293
Jurij Hanzel, Christopher Ma, Vipul Jairath
{"title":"Upadacitinib for the treatment of moderate-to-severe Crohn's disease.","authors":"Jurij Hanzel, Christopher Ma, Vipul Jairath","doi":"10.2217/imt-2023-0293","DOIUrl":"10.2217/imt-2023-0293","url":null,"abstract":"<p><p>Despite an increasing number of therapies for Crohn's disease (CD), half of patients do not respond to initial treatment or lose response over time, highlighting the need for novel therapies. Inhibition of Janus kinases (JAKs) has emerged as an important therapeutic target for CD. Upadacitinib is an orally administered selective JAK1 inhibitor, which is effective for the induction and maintenance of remission in moderately-to-severely active CD, including in patients with prior failure of biological therapy. Nonselective JAK inhibition has been associated with thromboembolic disease, cardiovascular events and malignancy in patients older than 50 years with rheumatoid arthritis and pre-existing cardiovascular risk factors, which should be considered upon prescription. Upadacitinib is the first and currently only oral advanced therapy for CD.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"345-357"},"PeriodicalIF":2.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes for pembrolizumab stratified by pemetrexed maintenance post pembrolizumab-platinum-pemetrexed induction in metastatic non-small-cell lung cancer. 转移性非小细胞肺癌患者使用彭博拉珠单抗-铂-培美曲塞诱导治疗后培美曲塞维持治疗的疗效分层。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-03-15 DOI: 10.2217/imt-2023-0313
Jerome H Goldschmidt, Srinivas Annavarapu, Divea Venkatasetty, Yunfei Wang, Melissa L Santorelli, Thomas Burke, Nathan A Pennell
{"title":"Outcomes for pembrolizumab stratified by pemetrexed maintenance post pembrolizumab-platinum-pemetrexed induction in metastatic non-small-cell lung cancer.","authors":"Jerome H Goldschmidt, Srinivas Annavarapu, Divea Venkatasetty, Yunfei Wang, Melissa L Santorelli, Thomas Burke, Nathan A Pennell","doi":"10.2217/imt-2023-0313","DOIUrl":"10.2217/imt-2023-0313","url":null,"abstract":"<p><p><b>Aim:</b> We assessed treatment patterns and outcomes in patients with metastatic nonsquamous non-small-cell lung cancer (mNSCLC) who initiated first-line pembrolizumab-platinum-pemetrexed (induction) in US community oncology settings. <b>Methods:</b> Patients initiating induction were retrospectively identified. Patients continuing pembrolizumab afterward underwent chart review. Clinical outcomes were described by maintenance pemetrexed exposure after inverse probability of treatment weighting (IPTW). <b>Results:</b> Median induction pembrolizumab and pemetrexed durations were 5.1 and 4.2 months. Among patients continuing pembrolizumab after induction, 64% received maintenance pemetrexed. Common discontinuation reasons for induction pemetrexed were completion of planned therapy (79%) and partial response (68%) and progressive disease (38%) and toxicity (29%) for maintenance pemetrexed. After IPTW, median overall survival and real-world progression-free survival were longer in patients continuing pembrolizumab with versus without maintenance pemetrexed (20.3 vs 12.0 months and 10.3 vs 5.8 months, respectively). <b>Conclusion:</b> Patient characteristics and planned treatment decisions affect maintenance pemetrexed utilization in the community oncology setting.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"453-464"},"PeriodicalIF":2.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140131350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment and prognostic implications of strong PD-L1 expression in primary hepatic sarcomatoid carcinoma. 原发性肝肉瘤样癌中 PD-L1 强表达对治疗和预后的影响。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-02-16 DOI: 10.2217/imt-2023-0243
Subathra Radhakrishnan, Catherine Ann Martin, Mukul Vij, Komalavalli Subbiah, Lexmi Priya Raju, Gowripriya Gowrishankar, Vidya Harini Veldore, Ilankumaran Kaliamoorthy, Ashwin Rammohan, Mohamed Rela
{"title":"Treatment and prognostic implications of strong PD-L1 expression in primary hepatic sarcomatoid carcinoma.","authors":"Subathra Radhakrishnan, Catherine Ann Martin, Mukul Vij, Komalavalli Subbiah, Lexmi Priya Raju, Gowripriya Gowrishankar, Vidya Harini Veldore, Ilankumaran Kaliamoorthy, Ashwin Rammohan, Mohamed Rela","doi":"10.2217/imt-2023-0243","DOIUrl":"10.2217/imt-2023-0243","url":null,"abstract":"<p><p>Primary hepatic sarcomatoid carcinoma (HSC) is an extremely rare and aggressive subtype of primary liver cancer. HSC has uncertain pathogenesis and dismal prognosis with overall survival of only 8.3 months. The molecular alterations of HSC are also not well understood. In this study, the authors describe a patient who presented with a large liver mass. The patient underwent complete surgical resection and histological examination demonstrated HSC, infiltrating the stomach. PD-L1 was strongly positive in the tumor cells. The patient was started on anti-PD-L1 immunotherapy postsurgery and is doing well 15 months after surgical resection. Tumor whole exome sequencing revealed genetic alterations in <i>TP53</i>, <i>NF2</i> and <i>MAGEC3</i> genes, indicating their potential role in tumor development.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"371-379"},"PeriodicalIF":2.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune checkpoint inhibitors in follicular dendritic cell sarcoma. 免疫检查点抑制剂在滤泡树突状细胞肉瘤中的应用。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-02-16 DOI: 10.2217/imt-2023-0230
Tarek Assi, Axel Le Cesne
{"title":"Immune checkpoint inhibitors in follicular dendritic cell sarcoma.","authors":"Tarek Assi, Axel Le Cesne","doi":"10.2217/imt-2023-0230","DOIUrl":"10.2217/imt-2023-0230","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"341-344"},"PeriodicalIF":2.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信